Huang J.,Chengdu Womens and Childrens Central Hospital |
Ni S.,Tianjin Central Hospital of Gynecology Obstetrics |
Li D.,University of Sichuan |
He Y.,University of Sichuan
Genetic Testing and Molecular Biomarkers | Year: 2015
Objective: Previous studies have shown that miRNA plays a key role in cervical carcinogenesis. Interleukin (IL)-1α can promote tumor growth, invasion, migration, and angiogenesis. An insertion/deletion polymorphism (rs3783553) in the IL1A 3′ untranslated region may disrupt a binding site for miR-122 and miR-378 and thus change the transcription of IL-1α. The purpose of this study was to evaluate the association between the rs3783553 polymorphism and the risk of cervical squamous cell carcinoma (CSCC). Methods: Polymerase chain reaction was used to genotype the IL1A rs3783553 polymorphism in 235 patients with CSCC and 326 controls. Results: We found that the ins/ins genotype had a decreased risk to develop CSCC (odds ratio [OR]=0.48, 95% confidence interval [CI], 0.25-0.95). However, no significant association was observed between the IL1A rs3783553 genotype and clinical features. Conclusion: These findings indicate that the IL1A rs3783553 polymorphism may be associated with the etiology of CSCC. © 2015, Mary Ann Liebert, Inc.
Zhang S.,Tianjin Central Hospital of Gynecology Obstetrics
Chinese Journal of Clinical Oncology | Year: 2014
Objective: This study aims to evaluate the performance of the predictive model risk of ovarian malignancy algorithm (ROMA) using serum human epididymis protein 4 (HE4) and CA125 for discriminating benign from malignant pelvic masses. Methods: The electrochemical luminescence method was carried out before and after the menopause prediction model (ROMA) to detect serum HE4 and CA125 levels of patients admitted in hospital for surgery of pelvic masses or ovarian cyst. Patients were classified into high- and low-risk groups to evaluate the value of the applied prediction model. Results: Of the 1683 patients evaluated, 1448 had pelvic benign disease and 235 had pelvic malignancy, including 106 EOC. In the pathological diagnosis of patients with benign pelvic masses, 1356 cases were classified into the low-risk group with a specificity of 93.6%. A total of 121 cases of pelvic malignant tumors with sensitivity of 80.7% and 20 cases of border ovarian epithelial tumor with sensitivity of 28.2% were categorized in the high-risk group. EOC cases (93) were also classified in the high-risk group, with sensitivity of 87.7%. The cases that were not classified in the high-risk group included 2 of mucous adenocarcinoma and 11 of clear cell carcinoma. Five cases of non-epithelial ovarian malignant tumor patients were classified into the high-risk group with a sensitivity of 38.5%. Thirty-five cases of ovarian malignant tumor patients with a sensitivity of 85.3% and one case of metastatic ovarian cancer patient with a sensitivity of 25.0% were categorized in the high-risk group. Conclusions: ROMA can be successfully applied in pelvic malignant tumor patients to classify them into high-risk group. Most EOC patients belong to the high-risk group. ROMA can be used in patients with malignant EOC, especially during preliminary screening.
Zhang Y.,Tianjin Medical University |
Zhang Y.-S.,Tianjin Central Hospital of Gynecology Obstetrics |
Xue F.-X.,Tianjin Medical University
In Vitro Cellular and Developmental Biology - Animal | Year: 2016
The aims of this study are to establish an embryonic stem (ES) cell model of polycystic ovary syndrome and to characterize this ES cell line. ES cells were isolated and cultured from 322 wasted fertilized embryos from polycystic ovary syndrome (PCOS) patients in vitro. They were also characterized by development and differential markers. ES cells from PCOS subject present normal development profile with ES-specific markers such as OCT-4 and SSEA-4. These ES cells can also differentiate into three germ layer derivatives and form teratomas in vivo. ES cells from PCOS patients pose development and differentiation potentials as you would expect of cells from non-PCOS patients; therefore, they can be used as a cellular model to study the pathology of PCOS. © 2016 The Society for In Vitro Biology
Long M.-J.,Tianjin Medical University |
Wu F.-X.,Tianjin Medical University |
Li P.,Tianjin Central Hospital of Gynecology Obstetrics |
Liu M.,Tianjin Medical University |
And 2 more authors.
Cancer Letters | Year: 2012
MicroRNAs (miRNAs) play an important role in cancer initiation, progression and metastasis by regulating their target genes. Here, we found microRNA-10a (miR-10a) is upregulated in human cervical cancer and promotes the colony formation activity, migration and invasion of HeLa and C33A cells. Subsequently, CHL1 is confirmed as a target of miR-10a and is negatively regulated by miR-10a at mRNA and protein levels. Furthermore, knockdown of CHL1 expression results in increased colony formation activity, migration and invasion. Finally, overexpression of CHL1 lacked the 3'UTR abolished the effects of miR-10a. Our results may provide a strategy for blocking tumor metastasis. © 2012 Elsevier Ireland Ltd.
Kasai T.,Okayama University |
Chen L.,Tianjin Central Hospital of Gynecology Obstetrics |
Mizutani A.,Okayama University |
Kudoh T.,Okayama University |
And 3 more authors.
Journal of Stem Cells and Regenerative Medicine | Year: 2014
Nowadays, the cancer stem cells are considered to be significantly responsible for growth, metastasis, invasion and recurrence of all cancer. Cancer stem cells are typically characterized by continuous proliferation and self-renewal as well as by differentiation potential, while stem cells are considered to differentiate into tissue- specific phenotype of mature cells under the influence of micro-environment. Cancer stem cells should be traced to the stem cells under the influence of a micro-environment, which induces malignant tumors. In this review, we propose this micro-environment as a 'cancerous niche' and discuss its importance on the formation and maintenance of cancer stem cells with the recent experimental results to establish cancer stem cell models from induced pluripotent stem cells. These models of cancer stem cell will provide the great advantages in cancer research and its therapeutic applications in the future. © Journal of Stem Cells and Regenerative Medicine. All rights reserved.